stoxline Quote Chart Rank Option Currency Glossary
  
NanoVibronix, Inc. (NAOV)
1  0.01 (1.01%)    02-23 15:57
Open: 1.03
High: 1.03
Volume: 42,929
  
Pre. Close: 0.99
Low: 0.98
Market Cap: 2(M)
Technical analysis
2024-02-23 4:38:20 PM
Short term     
Mid term     
Targets 6-month :  1.45 1-year :  1.77
Resists First :  1.24 Second :  1.51
Pivot price 1.1
Supports First :  0.81 Second :  0.67
MAs MA(5) :  1.07 MA(20) :  1.07
MA(100) :  1.07 MA(250) :  2.35
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  19.8 D(3) :  27.4
RSI RSI(14): 44.7
52-week High :  4.34 Low :  0.72
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ NAOV ] has closed above bottom band by 29.0%. Bollinger Bands are 15.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.03 - 1.04 1.04 - 1.05
Low: 0.96 - 0.97 0.97 - 0.98
Close: 0.99 - 1 1 - 1.01
Company Description

NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally. NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York.

Headline News

Thu, 22 Feb 2024
Is NanoVibronix Inc (NAOV) Stock a Smart Investment Thursday? - InvestorsObserver

Tue, 13 Feb 2024
Premarket Mover: NanoVibronix Inc (NAOV) Up 4.07% - InvestorsObserver

Mon, 12 Feb 2024
NanoVibronix Inc (NAOV) Stock: What Does the Chart Say Monday? - InvestorsObserver

Thu, 25 Jan 2024
Is NanoVibronix Inc (NAOV) a Stock to Watch After Gaining 30.49% This Week? - InvestorsObserver

Wed, 06 Dec 2023
NanoVibronix Featured in Your Bladder Health Magazine - Business Wire

Wed, 30 Aug 2023
Why NanoVibronix Shares Are Trading Higher By 49%; Here Are 20 Stocks Moving Premarket - Ambarella (NASDA - Benzinga

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical Devices
Shares Out 2 (M)
Shares Float 2 (M)
Held by Insiders 0.5 (%)
Held by Institutions 5.9 (%)
Shares Short 5 (K)
Shares Short P.Month 7 (K)
Stock Financials
EPS -3.16
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.54
Profit Margin 0 %
Operating Margin -146.3 %
Return on Assets (ttm) -41.7 %
Return on Equity (ttm) -126.4 %
Qtrly Rev. Growth 372.2 %
Gross Profit (p.s.) 0
Sales Per Share 0.48
EBITDA (p.s.) -2.04
Qtrly Earnings Growth 0 %
Operating Cash Flow -4 (M)
Levered Free Cash Flow -2 (M)
Stock Valuations
PE Ratio -0.32
PEG Ratio 0
Price to Book value 0.39
Price to Sales 2.04
Price to Cash Flow -0.47
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android